Research programme: Gram-negative infection therapeutics - Asinex

Drug Profile

Research programme: Gram-negative infection therapeutics - Asinex

Latest Information Update: 12 Jul 2016

Price : $50

At a glance

  • Originator ASINEX
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Gram-negative infections

Most Recent Events

  • 12 Jul 2016 Research programme: Gram-negative infection therapeutics - Asinex is available for licensing as of 12 Jul 2016. http://www.asinex.com/
  • 12 Jul 2016 Early research in Gram-negative infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top